KZA kazia therapeutics limited

FTD also allows for ‘rolling review’, whereby Kazia may submit...

  1. 1,737 Posts.
    lightbulb Created with Sketch. 96
    FTD also allows for ‘rolling review’, whereby Kazia may submit completed sections of the paxalisib NDA as they become available, rather than at the end of development • Kazia consequently plans to begin initial preparatory activities for NDA filing for paxalisib in CY2021

    Awesome smile.png
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.